Home › Research › Biomarkers
Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community-based study
Janina Krell-Roesch, Isabella Zaniletti, Jeremy A Syrjanen, Walter K Kremers, Alicia Algeciras-Schimnich, Jeffrey L Dage, Argonde C van Harten, Julie A Fields et al.. Alzheimer's & dementia (Amsterdam, Netherlands), 2023-07-30
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
P-tau181 (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.41-3.00, p < 0.001), p-tau217 (OR 1.70, 95% CI 1.10-2.61, p = 0.016), and t-tau (OR 1.44, 95% CI 1.08-1.92, p = 0.012) were associated with appetite change. We also found that p-tau181 and p-tau217 were associated with increased symptoms of agitation (OR 1.93, 95% CI 1.20-3.11, p = 0.007 and OR 2.04, 95% CI 1.21-3.42, p = 0.007, respectively), and disinhibition (OR 2.39, 95% CI 1.45-3.93, p = 0.001 and OR 2.30, 95% CI 1.33-3.98, p = 0.003, respectively). Aβ42/Aβ40 and NfL were not associated with NPS. Higher plasma-derived p-tau181 and p-tau217 levels are associated with increased symptoms of appetite change, agitation, and disinhibition. These findings may support the validity of plasma tau biomarkers for predicting behavioral symptoms that often accompany cognitive impairment. HIGHLIGHTS: We studied 1005 community-dwelling persons aged ≥ 50 yearsHigher plasma tau levels are associated with increased neuropsychiatric symptomsAβ42/Aβ40 and NfL are not associated with neuropsychiatric symptomsClinicians should treat neuropsychiatric symptoms in persons with high plasma-derived tau.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Krell-Roesch, J., Zaniletti, I., Syrjanen, J. A., Kremers, W. K., Algeciras-Schimnich, A., Dage, J. L., et al. (2023). Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community-based study. Alzheimer's & dementia (Amsterdam, Netherlands). https://doi.org/10.1002/dad2.12461
Vancouver
Krell-Roesch J, Zaniletti I, Syrjanen JA, Kremers WK, Algeciras-Schimnich A, Dage JL, et al. Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community-based study. Alzheimer's & dementia (Amsterdam, Netherlands). 2023. doi:10.1002/dad2.12461. PMID: 37529120.
BibTeX
@article{krellroesch2023-37529120,
author = {Krell-Roesch, Janina and Zaniletti, Isabella and Syrjanen, Jeremy A and Kremers, Walter K and Algeciras-Schimnich, Alicia and Dage, Jeffrey L and van Harten, Argonde C and Fields, Julie A and others},
title = {{Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community-based study}},
journal = {Alzheimer's \& dementia (Amsterdam, Netherlands)},
year = {2023},
doi = {10.1002/dad2.12461},
pmid = {37529120},
url = {https://doi.org/10.1002/dad2.12461}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- P-tau181 (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.41-3.00, p < 0.001), p-tau217 (OR 1.70, 95% CI 1.10-2.61, p = 0.016), and t-tau (OR 1.44, 95% CI 1.08-1.92, p = 0.012) were associated with appetite change.
- We also found that p-tau181 and p-tau217 were associated with increased symptoms of agitation (OR 1.93, 95% CI 1.20-3.11, p = 0.007 and OR 2.04, 95% CI 1.21-3.42, p = 0.007, respectively), and disinhibition (OR 2.39, 95% CI 1.45-3.93, p = 0.001 and OR 2.30, 95% CI 1.33-3.98, p = 0.003, respectively).
- Aβ42/Aβ40 and NfL were not associated with NPS.
- Higher plasma-derived p-tau181 and p-tau217 levels are associated with increased symptoms of appetite change, agitation, and disinhibition.
- These findings may support the validity of plasma tau biomarkers for predicting behavioral symptoms that often accompany cognitive impairment.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants1,005
- Effect sizeOR 1.70; OR 1.44; OR 1.93
- Evidence strengthLow
How this study scored 68/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 38 of the 56 points we could judge it on, which is 68 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (Amsterdam, Netherlands)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,005 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37529120) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 38 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 38 of the 56 points we could judge it on is 68 out of 100. |
| Total | 68 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.